Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
UCLA Medical Center
mi
from
Los Angeles, CA
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
National Jewish Health
mi
from
Denver, CO
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
University of Miami - Batchelor Children's Research Institute
mi
from
Miami, FL
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
University of Miami - Batchelor Children's Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Allergy Associates of the Palm Beaches, PA
mi
from
North Palm Beach, FL
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Allergy Associates of the Palm Beaches, PA
mi
from
North Palm Beach, FL
Click here to add this to my saved trials
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
University of South Florida
mi
from
Saint Petersburg, FL
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
University of South Florida
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Emory Children's Center
mi
from
Atlanta, GA
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Emory Children's Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Michigan, Wayne State University
mi
from
Detroit, MI
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Michigan, Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Washington University Medical Center
mi
from
Saint Louis, MO
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Washington University Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Penn State University
mi
from
Hershey, PA
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Penn State University
mi
from
Hershey, PA
Click here to add this to my saved trials
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Baylor Texas Children's Hospital
mi
from
Houston, TX
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Baylor Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Richmond at VCU, VCU Medical Center
mi
from
Richmond, VA
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Richmond at VCU, VCU Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Ottawa Hospital, Division of Infectious Disease and Respirology
mi
from
Ottawa,
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Ottawa Hospital, Division of Infectious Disease and Respirology
mi
from
Ottawa,
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
University of Southern California CRS (1201)
mi
from
Los Angeles, CA
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
University of Southern California CRS (1201)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Ucsd, Avrc Crs (701)
mi
from
San Diego, CA
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Ucsd, Avrc Crs (701)
mi
from
San Diego, CA
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
University of Miami AIDS CRS (901)
mi
from
Miami, FL
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
University of Miami AIDS CRS (901)
mi
from
Miami, FL
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
The Ponce de Leon Ctr. CRS (5802)
mi
from
Atlanta, GA
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
The Ponce de Leon Ctr. CRS (5802)
mi
from
Atlanta, GA
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Northwestern University CRS (2701)
mi
from
Chicago, IL
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Northwestern University CRS (2701)
mi
from
Chicago, IL
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Rush Univ. Med. Ctr. ACTG CRS (2702)
mi
from
Chicago, IL
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Rush Univ. Med. Ctr. ACTG CRS (2702)
mi
from
Chicago, IL
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp. ACTG CRS (107)
mi
from
Boston, MA
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp. ACTG CRS (107)
mi
from
Boston, MA
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Cornell CRS (7804)
mi
from
New York, NY
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Cornell CRS (7804)
mi
from
New York, NY
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Weill Med. College of Cornell Univ., The Cornell CTU -Chelsea (7803)
mi
from
New York, NY
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Weill Med. College of Cornell Univ., The Cornell CTU -Chelsea (7803)
mi
from
New York, NY
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Columbia Physicians and Surgeons CRS (30329)
mi
from
New York, NY
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Columbia Physicians and Surgeons CRS (30329)
mi
from
New York, NY
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
mi
from
Rochester, NY
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
mi
from
Rochester, NY
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
3201 Chapel Hill CRS
mi
from
Chapel Hill, NC
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
3201 Chapel Hill CRS
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Greensboro CRS (3203)
mi
from
Greensboro, NC
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Greensboro CRS (3203)
mi
from
Greensboro, NC
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
The Ohio State Univ. AIDS CRS (2301)
mi
from
Columbus, OH
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
The Ohio State Univ. AIDS CRS (2301)
mi
from
Columbus, OH
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
The Miriam Hospital ACTG CRS (2951)
mi
from
Providence, RI
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
The Miriam Hospital ACTG CRS (2951)
mi
from
Providence, RI
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Vanderbilt Therapeutics CRS (3652)
mi
from
Nashville, TN
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Therapeutics CRS (3652)
mi
from
Nashville, TN
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Puerto Rico-AIDS CRS (5401)
mi
from
San Juan,
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Puerto Rico-AIDS CRS (5401)
mi
from
San Juan,
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Harbor-UCLA Med. Ctr. CRS (603)
mi
from
Torrance, CA
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Harbor-UCLA Med. Ctr. CRS (603)
mi
from
Torrance, CA
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
Washington University CRS (2101)
mi
from
Saint Louis, MO
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
Washington University CRS (2101)
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated:  12/31/1969
31443 Trinity Health and Wellness Center CRS
mi
from
Dallas, TX
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Status: Enrolling
Updated: 12/31/1969
31443 Trinity Health and Wellness Center CRS
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)
An Open-label Study to Evaluate the Pharmacokinetics and Safety of BMS-663068 in Subjects With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End‑Stage Renal Dysfunction
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Miami, FL
A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)
An Open-label Study to Evaluate the Pharmacokinetics and Safety of BMS-663068 in Subjects With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End‑Stage Renal Dysfunction
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated:  12/31/1969
E Study Site
mi
from
Las Vegas, NV
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated: 12/31/1969
E Study Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated:  12/31/1969
CD02 Investigational site
mi
from
Fountain Valley, CA
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated: 12/31/1969
CD02 Investigational site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated:  12/31/1969
CD02 Investigational site
mi
from
Long Beach, CA
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated: 12/31/1969
CD02 Investigational site
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated:  12/31/1969
CD02 Investigational site
mi
from
Los Angeles, CA
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated: 12/31/1969
CD02 Investigational site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated:  12/31/1969
CD02 Investigational site
mi
from
Palm Springs, CA
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated: 12/31/1969
CD02 Investigational site
mi
from
Palm Springs, CA
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated:  12/31/1969
CD02 Investigational Site
mi
from
San Francisco, CA
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated: 12/31/1969
CD02 Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated:  12/31/1969
CD02 Investigational Site
mi
from
New Haven, CT
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated: 12/31/1969
CD02 Investigational Site
mi
from
New Haven, CT
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated:  12/31/1969
CD02 Investigational site
mi
from
Norwalk, CT
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated: 12/31/1969
CD02 Investigational site
mi
from
Norwalk, CT
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated:  12/31/1969
CD02 Investigational Site
mi
from
Washington,
A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Status: Enrolling
Updated: 12/31/1969
CD02 Investigational Site
mi
from
Washington,
Click here to add this to my saved trials